Revenue segments as reported by the company.

Immunology

Hematologic Oncology

Aesthetics

Neuroscience

Eye Care

Women's Health

Other Key Products

All other

Revenue Segments

Gross Profit, Operating Income, and Net Income as a percentage of Revenue

Gross Margin

Operating Margin

Profit Margin

Margins

An operating expense is an expense a business incurs through its normal business operations. Often abbreviated as OPEX.

Selling, general and administrative

Research and development

Acquired in-process research and development

Other operating expense

Operating Expenses

Year over year growth in Revenue and Operating Expenses.

Revenue Y/Y

OpEx Y/Y

Growth

Shares outstanding refer to a company's stock currently held by all its shareholders, including share blocks held by institutional investors and restricted shares owned by the company's officers and insiders.

Outstanding Shares

Market Cap

Also known as Price/Sales Ratio. Calculated using Average market cap for the quarter / Annualized quarterly revenue.

Revenue Multiple

AbbVie

AbbVie, Inc. is a research-based biopharmaceutical company, which engages in the development and sale of pharmaceutical products. It focuses on treating conditions such as chronic autoimmune diseases in rheumatology, gastroenterology, and dermatology, oncology, including blood cancers, virology, hepatitis C virus (HCV) and human immunodeficiency virus (HIV), neurological disorders, such as Parkinson's, metabolic, comprising thyroid disease and complications associated with cystic fibrosis, pain associated with endometriosis, and other serious health conditions. The company was founded on October 19, 2011 and is headquartered in North Chicago, IL.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

AbbVie surpasses Q4 earnings forecast, eyes growth amid challenges

AbbVie's strong performance in Q4 2022 exceeded expectations, driven by key products like SKYRIZI and RINVOQ. Despite challenges in revenue and HUMIRA erosion, the company is focused on innovation and growth opportunities. Strategic investments in R&D and BD aim to navigate market dynamics and drive future success.

AbbVie surpasses Q1 expectations, eyes international growth amid challenges

AbbVie's Q1 2023 performance exceeded expectations, driven by key product sales and strong international results. While facing challenges in the U.S. market and inflationary pressures, the company remains confident in its long-term growth prospects and strategic initiatives.

AbbVie surpasses Q2 expectations, eyes revenue growth opportunities

AbbVie's Q2 2023 earnings call highlighted strong financial performance, successful execution in key therapeutic areas, and a promising outlook for revenue growth. Despite challenges like biosimilar competition and market dynamics, the company remains confident in its ability to deliver value and maintain growth.

AbbVie exceeds Q3 expectations, focuses on pipeline growth strategies

AbbVie's strong Q3 performance driven by key products and growth platforms, with positive trial results.
Challenges in aesthetics sales and Medicare drug pricing program offset by long-term growth opportunities.
Confidence in pipeline assets and strategic focus on combination therapies for future growth.
Maintaining strong market positions and investing in transformative therapies for competitive advantage.

AbbVie exceeds Q4 expectations, eyes growth through strategic acquisitions

AbbVie's stellar performance in Q4 2023 showcased strong sales growth, successful pipeline advancements, and strategic acquisitions. While facing challenges such as pricing pressures and safety concerns, the company is well-positioned to capitalize on opportunities in expanding its portfolio and driving growth through innovation and strategic partnerships.

AbbVie exceeds Q1 expectations, raises full-year guidance on strong sales growth

AbbVie's Q1 performance exceeded expectations, with strong sales growth in key products. The company raised full-year guidance and remains confident in maintaining good access for its brands. Challenges in aesthetics sales and inventory management are being addressed for future growth.

AbbVie reports robust Q2 results and raises 2024 guidance

AbbVie's strong Q2 performance, raised guidance, and strategic acquisitions highlight its growth trajectory.
Despite near-term challenges, the company's focus on key growth areas positions it for long-term success.
Investments in innovation and market expansion underscore AbbVie's commitment to sustained growth.
Overall, AbbVie's performance in Q2 2024 reflects a resilient and forward-looking approach to business.

AbbVie reports strong Q3 performance, raises guidance and dividend

AbbVie's Q3 2024 performance showcased robust sales growth, increased dividend, and raised revenue guidance, reflecting financial strength and market leadership.
The company's focus on long-term sustainability through investments, acquisitions, and pipeline advancements highlights a commitment to innovation and growth.
While facing challenges in clinical trial management and market competition, AbbVie remains well-positioned to leverage opportunities in diverse therapeutic areas for future growth.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

AbbVie's (ABBV) Breakthrough Therapy Designation for Teliso-V is based on data from the phase II LUMINOSITY study.

AbbVie (ABBV) Gets FDA Breakthrough Tag for Lung Cancer Drug

Abbott Labs

Bristol-Myers

Caterpillar

General Dynamics

Hormel Foods

Lowe's

Mastercard

Oracle

Toronto-Dominion Bank

Verizon

We provide a summary of upcoming ex-dividend dates in a quick reference table. The table includes relevant data and key statistics as well as the next payout and pay date.

Upcoming Ex-Dividend Dates: January 6-17, 2022

NORTH CHICAGO, Ill., Jan. 5, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will announce its fourth-quarter and full-year 2021 financial results on Wednesday, February 2, 2022, before the market opens.

AbbVie to Host Fourth-Quarter and Full-Year 2021 Earnings Conference Call

Here is how AbbVie (ABBV) and Allakos Inc. (ALLK) have performed compared to their sector so far this year.

Has AbbVie (ABBV) Outpaced Other Medical Stocks This Year?

NORTH CHICAGO, Ill., Jan. 4, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) announced today that the U.S. Food and Drug Administration (FDA) granted Breakthrough Therapy Designation (BTD) to investigational telisotuzumab vedotin (Teliso-V) for the treatment of patients with advanced/metastatic epidermal growth factor receptor (EGFR) wild type, nonsquamous non-small cell lung cancer (NSCLC) with high levels of c-Met overexpression whose disease has progressed on or after platinum-based therapy.

AbbVie Announces U.S. FDA Granted Breakthrough Therapy Designation (BTD) to Telisotuzumab Vedotin (Teliso-V) for Previously Treated Non-Small Cell Lung Cancer

NORTH CHICAGO, Ill., Jan. 4, 2022 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the 40th Annual J.P.

AbbVie to Present at the 40th Annual J.P. Morgan Healthcare Conference

ARK Innovation ETF

Brunswick

Celanese

Crane Company

CVS Health

Evercore

Fortune Brands Home & Security

Huntington Bancshares

Kroger

Altria

Realty Income Corp

Schwab US Dividend Equity ETF

First Trust SMID Cap Rising Dividend Achievers ETF

Sherwin-Williams

Snap-on

AT&T

Universal Forest Products

Vanguard Dividend Appreciation ETF

Vanguard High Dividend Yield ETF

Whirlpool

Worthington Industries

Williams-Sonoma

We start out with a short list of guidelines that make it easier to identify dividend stocks that are still worth investing in right now.

The Best Dividend Stocks For January 2022

AllianceBernstein Hld

Camping World Hlds

Enbridge

EPR Properties

Sunoco

Exxon Mobil

These seven dividend stocks will provide a stable income and help investors like you develop a strong portfolio in 2022 The post 7 of the Best High-Yield Dividend Stocks for 2022 to Buy Now appeared first on InvestorPlace. More From InvestorPlace Stock Prodigy Who Found NIO at $2… Says Buy THIS Now Man Who Called Black Monday: “Prepare Now.

7 of the Best High-Yield Dividend Stocks for 2022 to Buy Now

Home Depot

Philip Morris

Are you looking for passive income? Ring in 2022 with blue chip stocks that pay you for holding them.

My Top 5 Dividend Stocks to Buy for 2022

AbbVie once again reported strong quarterly results with revenue growing in the double digits. But analysts are rather pessimistic that AbbVie will not be able to grow with a similar pace as in the last few years.

AbbVie: A Pick For Dividend Investors With A 4.2% Yield

Immunology medicine Rinvoq was green-lit to treat patients with psoriatic arthritis in the U.S.

Could This FDA Approval Create a Blockbuster Drug for AbbVie?

Amgen

BlackRock Taxable Municipal Bond Trust

BlackRock Science & Technology

Calamos Convertible Opportunities And Income Fund

Clorox

Digital Realty Trust

DNP Select Income Fund Inc

Enterprise Products Partners

Fastenal

Flaherty & Crumrine Preferred Securities Income Fund Inc

Johnson & Johnson

Kimberly-Clark

Lockheed Martin

McDonald's

NextEra Energy

Annaly Capital

PIMCO Dynamic Income Fund

Invesco QQQ

Cohen & Steers Quality Income Realty Fund

iShares 20+ Year Treasury Bond ETF

Texas Instruments

No portfolio or strategy can be perfect. But can there be a strategy that can work well in a bull market, a bear market, or a stagnant market, generate a decent income, and conserve capital, all at the same time? We also want our strategy to avoid roller-coaster rides of index investing, have low volatility and limited drawdowns in case of deep corrections.

The Near-Perfect Portfolio For The Bull Markets And The Bear Markets

Brookfield Renewable Partners

Pfizer

Could these dividend stocks be big winners in the new year?

5 Dividend Stocks To Watch In 2022

A solid year and an excellent third-quarter report from AbbVie has ABBV stock look like it is one of the best stocks to buy for 2022. The post Best Stocks for 2022: Why AbbVie Looks Like High Dividend Growth Stock appeared first on InvestorPlace.

Best Stocks for 2022: Why AbbVie Looks Like High Dividend Growth Stock

News for AbbVie Stock (ABBV)